Chapter 1

Introduction to Alzheimer's Disease

Understanding the global challenge and the path to a unified solution

1.1 The Global Burden of Alzheimer's Disease

Alzheimer's disease (AD) represents one of the most significant public health challenges of the 21st century. As the world's population ages, the prevalence of this devastating neurodegenerative disorder continues to rise at an alarming rate. Understanding the scope and impact of AD is essential for appreciating why standardized approaches to treatment and assessment are not merely beneficial but absolutely necessary.

The World Health Organization has declared dementia a global public health priority. Alzheimer's disease, which accounts for approximately 60-70% of all dementia cases, disproportionately affects older adults but can also manifest in younger individuals through early-onset forms. The disease not only devastates the individuals affected but also places enormous burdens on families, caregivers, healthcare systems, and economies worldwide.

Regional Distribution

The burden of AD is unevenly distributed across the globe, with significant variations in prevalence, diagnosis rates, and access to treatment:

Region	Cases (millions)	% of Global Total	Growth Rate
Asia Pacific	23.6	43%	+4.1%/year
Europe	10.2	18%	+1.8%/year
Americas	10.7	19%	+2.3%/year
Africa	4.0	7%	+3.8%/year
Middle East	3.5	6%	+3.5%/year

1.2 The Pathophysiology of Alzheimer's Disease

Alzheimer's disease is characterized by a complex interplay of pathological processes that ultimately lead to progressive neurodegeneration and cognitive decline. Understanding these mechanisms is crucial for developing effective treatments and for appreciating why the NAD+ homeostasis approach represents such a significant advancement.

The Amyloid Hypothesis

For decades, the amyloid hypothesis has dominated AD research. This theory proposes that the accumulation of amyloid-beta (Aβ) peptides in the brain triggers a cascade of events leading to neuronal death. Key aspects include:

• Amyloid precursor protein (APP) processing: Abnormal cleavage of APP by β-secretase and γ-secretase produces Aβ peptides, particularly the 42-amino acid form (Aβ42)
• Oligomer formation: Soluble Aβ oligomers are now recognized as more neurotoxic than the insoluble plaques
• Plaque accumulation: Extracellular amyloid plaques serve as a hallmark pathological feature but may represent a protective sequestration mechanism
• Synaptic dysfunction: Aβ oligomers disrupt synaptic transmission and plasticity

Tau Pathology

The tau hypothesis focuses on the hyperphosphorylation and aggregation of tau protein:

• Normal function: Tau stabilizes microtubules in neurons, essential for axonal transport
• Hyperphosphorylation: Abnormal kinase activity leads to excessive tau phosphorylation
• Neurofibrillary tangles (NFTs): Hyperphosphorylated tau aggregates into paired helical filaments that form NFTs
• Spread pattern: Tau pathology follows a predictable pattern (Braak staging), correlating with cognitive decline

Neuroinflammation

Chronic inflammation in the brain plays a significant role in AD progression:

• Microglial activation: Brain-resident immune cells become chronically activated, releasing pro-inflammatory cytokines
• Astrocyte reactivity: Astrocytes adopt a neurotoxic phenotype, impairing their normal supportive functions
• Cytokine storm: Elevated levels of IL-6, TNF-α, and other inflammatory mediators contribute to neuronal damage
• Blood-brain barrier disruption: Inflammation compromises BBB integrity, allowing peripheral immune cells and toxins to enter the brain

Mitochondrial Dysfunction

Mitochondrial abnormalities are increasingly recognized as central to AD pathogenesis:

• Energy deficit: Neurons require enormous amounts of ATP; mitochondrial dysfunction leads to energy failure
• Oxidative stress: Dysfunctional mitochondria produce excessive reactive oxygen species (ROS)
• Calcium dysregulation: Impaired mitochondrial calcium buffering affects synaptic function
• NAD+ depletion: Mitochondrial dysfunction is both a cause and consequence of NAD+ insufficiency

1.3 The Disease Continuum

Alzheimer's disease progresses through distinct stages, though the boundaries between stages are often blurred in clinical practice. Understanding this continuum is essential for appropriate intervention timing:

1.4 Risk Factors and Protective Factors

Non-Modifiable Risk Factors

Factor	Impact	Notes
Age	Risk doubles every 5 years after 65	Strongest risk factor
APOE ε4 allele	3-12x increased risk	One copy: 3x; Two copies: 12x
Family history	2-3x increased risk	First-degree relative with AD
Female sex	~2/3 of AD patients are women	Possibly hormonal factors
Down syndrome	Nearly universal AD by age 40	Extra copy of APP gene

Modifiable Risk Factors

The Lancet Commission on Dementia (2024 update) identified 14 modifiable risk factors that together account for approximately 45% of dementia cases:

1. Lower education - Early life
2. Hearing loss - Midlife
3. Traumatic brain injury - Midlife
4. Hypertension - Midlife
5. Excessive alcohol consumption - Midlife
6. Obesity - Midlife
7. Smoking - Later life
8. Depression - Later life
9. Social isolation - Later life
10. Physical inactivity - Later life
11. Diabetes - Later life
12. Air pollution - Later life
13. Vision loss - Later life (new in 2024)
14. High LDL cholesterol - Later life (new in 2024)

1.5 The Need for Standardization

Despite decades of research and billions of dollars invested, Alzheimer's disease treatment has been characterized by fragmentation, inconsistency, and limited success. The WIA-ALZHEIMERS standard addresses these challenges through unified approaches:

Current Challenges

• Diagnostic inconsistency: Different centers use different criteria and biomarkers
• Data incompatibility: Research findings cannot be compared or aggregated effectively
• Treatment fragmentation: Multiple therapeutic approaches exist in silos
• Access inequality: Advanced diagnostics and treatments are unavailable in many regions
• Trial inefficiency: Clinical trials struggle with heterogeneous populations and endpoints

The WIA Solution

The WIA-ALZHEIMERS standard provides:

• Unified data formats: Standardized schemas for all AD-related data
• Common APIs: Interoperable interfaces for system integration
• Standardized protocols: Consistent measurement and treatment procedures
• Global accessibility: Open standards accessible to all healthcare providers
• NAD+ focus: A unifying biomarker and therapeutic target

1.6 The Philosophy of 弘益人間

The WIA-ALZHEIMERS standard is built upon the ancient Korean philosophy of 弘益人間 (Hongik Ingan), meaning "to broadly benefit humanity." This philosophy guides every aspect of the standard:

• Universal access: The standard is freely available to all
• Patient-centered: All decisions prioritize patient welfare
• Evidence-based: Only scientifically validated approaches are included
• Continuously improving: The standard evolves with new research
• Inclusive: Designed for use across all healthcare settings and resource levels